Lilly Announces New Investment at the BIO Convention

This multi-million dollar investment is further fueling research and development of multi-specific therapeutics.

Eli Lilly and Company announced yesterday at the BIO International Convention a multi-million dollar investment to expand its existing biotechnology capabilities.

This investment is further fueling research and development of multi-specific therapeutics, in which two or more distinct mechanisms of action are engineered in one molecule with the goal of providing enhanced efficacy with an improved safety profile.

Lilly already has several multi-specific therapeutics in preclinical development, including a co-agonist peptide being studied as a potential treatment for diabetes that is anticipated to enter clinical development by the end of this year. Lilly is hiring additional biochemists and biologists to further support its important work in multi-s